ICLE 2022 | Applying CRISPR-Cas technology in advancing autologous T-cell therapies

Crispr-Cas9 technology as a gene editing tool has enabled the knockout of various inhibitory and endogenous T-cell receptors in the allogeneic setting. Mateusz Legut, PhD, New York Genome Center, New York, NY, describes issues with using Crispr-Cas9 in developing autologous T-cell therapies, including various editing efficiencies, off-targets and chromosomal abnormalities. Dr Legut additionally highlights research using lentiviral vector-mediated overexpression to screen the genome for novel genes that are potentially beneficial for T-cell therapies. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.”